{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-032513","form_type":"8-K","ticker":"TNGX","cik":"0001819133","company_name":"Tango Therapeutics, Inc.","filed_at":"2024-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.673961+00:00","generated_at":"2026-06-04T15:37:03.218719+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tango Therapeutics Q4 2023 net loss $30.8M; cash $336.9M; pipeline advances","bullets":["Net loss Q4 2023 $30.8M ($0.32/sh); full year net loss $101.7M ($1.08/sh).","Cash $336.9M at Dec 31, 2023; plus $41.7M from Jan 2024 ATM; runway into late 2026.","Four phase 1/2 trials ongoing; TNG908 clinical data expected 2024; first patient dosed for TNG348.","FDA Orphan Drug Designation granted for TNG462 for soft tissue sarcomas.","Appointed Chief Regulatory Officer, Chief Development Operations Officer, Chief Legal Officer."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-032513","json":"https://secwatch.observer/filing/0000950170-24-032513.json","markdown":"https://secwatch.observer/filing/0000950170-24-032513.md","text":"https://secwatch.observer/filing/0000950170-24-032513.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819133/000095017024032513/0000950170-24-032513-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819133/000095017024032513/tngx-20220810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T15:37:03.218719+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b4c0860ceb33e842eedc8622b79a9980d4b1e6b3","claim":"Tango Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"On March 18, 2024, Tango Therapeutics, Inc. (Tango or the Company) issued a press release relating to its results of operations and financial condition for the quarter and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819133/000095017024032513/0000950170-24-032513-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}